---
title: "CSPC Innovation Pharmaceutical's Unit Gets NMPA's Nod for Asthma Drug"
date: "2025-02-11 13:00:53"
summary: "CSPC Innovation Pharmaceutical said its subsidiary, Jushi Biopharmaceutical, received approval from China's National Medical Products Administration for a new indication for its omalizumab biosimilar, Enyitan, according to a Monday filing with the Shenzhen Bourse. The drug is now authorized for treating moderate to severe persistent allergic asthma, its second approved..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

CSPC Innovation Pharmaceutical said its subsidiary, Jushi Biopharmaceutical, received approval from China's National Medical Products Administration for a new indication for its omalizumab biosimilar, Enyitan, according to a Monday filing with the Shenzhen Bourse.

The drug is now authorized for treating moderate to severe persistent allergic asthma, its second approved indication in China. Enyitan was previously approved for chronic spontaneous urticaria.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250211:G2466030:0/)
